<DOC>
	<DOCNO>NCT01762878</DOCNO>
	<brief_summary>GSK2269557 potent highly selective inhale phosphoinositides 3-kinases -delta ( PI3K-delta ) inhibitor develop anti-inflammatory agent treatment inflammatory airway disease . GSK2269557 already administer nebulized solution single repeat dos human well tolerate across range dos use . The purpose study evaluate safety , tolerability pharmacokinetics single repeat inhaled dos GSK2269557 dry powder . This study first administration dry powder GSK2269557 human . Part A consist four treatment period separate least 14 day wash period . In treatment period 12 subject receive GSK2269557 4 subject receive placebo . The dos GSK2269557 plan Part A 100 microgram ( mcg ) , 500 mcg 3000 mcg . Blinded safety available pharmacokinetic ( PK ) data review dose escalation . Part B parallel group design conduct separate group subject Part A . Nine subject receive repeat dos GSK2269557 3 subject receive repeat dos placebo 14 day . The total daily dose dose well tolerated Part A . The study duration , include screen follow-up , expect exceed 82 day subject part A 55 day subject part B study .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics Single Repeat Doses Dry Powder Formulation GSK2269557 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Subjects current daily cigarette smoker . Must smoke regularly 12month period precede screen visit pack history &gt; = 5 pack year ( number pack year = number cigarette per day/20 x number year smoke Normal spirometry ( FEV1 &gt; = 80 % predict ) screening . Single QTcF &lt; 450 millisecond ( msec ) ; QTcF &lt; 480 msec subject Right Bundle Branch Block Currently healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac test . A subject clinical abnormality laboratory parameter outside reference range expect population study may include Investigator believe find unlikely introduce additional risk factor interfere study procedure outcome Between 18 50 year age inclusive , time signing inform consent A female subject eligible participate nonchildbearing potential define premenopausal female document hysterectomy , bilateral oophorectomy bilateral salpingectomy postmenopausal define 12 month spontaneous amenorrhea . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method f wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method Male subject female partner childbearing potential must agree use one contraception method . Body weight &gt; = 50 kilogram ( kg ) body mass index ( BMI ) within range 18 31 kg/meter^2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form Subjects unable produce total weight least 0.100 gram ( g ) select sputum screening Subjects whose primary consumption tobacco via method cigarette ( manufacture selfrolled ) . Primary method tobacco consumption exclude include , limited pipe cigar Urinary cotinine level screen &lt; 30 nanogram ( ng ) /mL A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) A history congestive heart failure , coronary insufficiency clinically significant cardiac arrhythmia would contraindicate subject 's participation study A positive prestudy drug/alcohol screen A positive test HIV antibody History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure four new chemical entity within 12 month prior first dose day Unable refrain use prescription nonprescription drug ( except simple analgesic ) , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety The subject receive type vaccination within 4 week first dose investigational product , expect vaccinate within 4 week last dose investigational product History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Where participation study would result donation blood blood product excess 500 mL within 90 day period Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitated Subjects asthma history asthma ( except childhood remit ) Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid 7 day prior first subsequent dos study medication collection last PK sample study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>Pi3K-delta</keyword>
	<keyword>GSK2269557</keyword>
	<keyword>safety</keyword>
	<keyword>dry powder inhaler</keyword>
</DOC>